Truist reiterates Boston Scientific stock rating on MiRus deal By Investing.com

Boston Scientific announced a $1.5 billion equity investment in MiRus, plus an option to acquire its SIEGEL TAVR business, and separately launched a $2 billion accelerated share repurchase under its existing $5 billion authorization. Truist reiterated a Buy rating and $85 price target, implying meaningful upside from the current $54.63 share price near the 52-week low of $52.52. The company’s fundamentals remain solid, with $20.6 billion revenue, 17.4% LTM growth, and a 68.9% gross margin.

Analysis

BSX is effectively running a two-engine strategy: financial engineering to support near-term EPS and an option on a longer-dated platform reset in structural heart. The market should treat the ASR as more than generic capital return; at this valuation, retiring stock amplifies per-share growth optics just as investors are revisiting whether the core franchise deserves a premium multiple despite slower macro-sensitive procedure growth.

The MiRus stake is the more important signal because it broadens BSX's competitive moat in a category where product differentiation can change reimbursement, adoption, and physician loyalty. If the smaller-profile delivery system performs as advertised, the second-order effect is not just share gain for one valve launch, but pressure on incumbents to defend with pricing, force-multiplier bundles, or earlier next-gen launches — which can compress industry economics before volume even shows up.

The main risk is that this becomes a capital allocation story without an underwriteable clinical catalyst. TAVR is a high-execution, low-forgiveness market: any delay in milestones, trial endpoints, or regulatory timing pushes the real value out 12-24 months, while the buyback only provides temporary downside support. That creates a setup where the stock can re-rate on headlines in the next few weeks, but the durable move depends on whether MiRus materially changes BSX’s growth algorithm by 2027-2030.

Consensus appears to be underweighting the asymmetry between modest dilution from the equity check and potentially large strategic optionality if the asset is real. The crowd likely views this as incremental pipeline insurance, but the more interesting read is that management is effectively paying up for a scarce external innovation source because internal TAVR attempts have not fully de-risked the category. That makes the call less about this quarter and more about whether BSX is buying a plausible endgame in a market where competitors may be forced into reactive rather than proactive capital deployment.

Key Decisions for Investors

• Long BSX vs. a basket of large-cap medtech peers over 3-6 months: the ASR should support relative performance, while MiRus introduces upside optionality that the peer set does not have. Use a 2-3% stop if the stock fails to hold the low-$50s base.
• Buy BSX Jan-2027 call spreads instead of common: the thesis is optionality on the TAVR platform, not near-term earnings alone. Structure for 2:1 to 3:1 payoff if the market starts pricing a credible launch pathway.
• Pair trade: long BSX / short a TAVR incumbent with higher dependence on the category over 6-12 months. The goal is to own the most credible innovation buyer while fading names that may face pricing or share pressure if MiRus gains traction.
• If BSX rallies sharply on buyback headlines in the next 1-2 weeks, fade part of the move and wait for milestone clarity; the ASR can pull forward demand, but the durable re-rating needs clinical validation.